Supriya Ghosh (Editor)

Adecatumumab

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Whole antibody

Target
  
EpCAM

CAS Number
  
503605-66-1

Source
  
Human

ATC code
  
none

ChemSpider
  
none

Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.

Adecatumumab has been used in clinical studies of treatment in colorectal, prostate and breast cancers. Phase II results were published in 2010.

References

Adecatumumab Wikipedia